Compare EVO & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | TBLA |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | Germany | United States |
| Employees | 4553 | 2000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 952.2M |
| IPO Year | N/A | N/A |
| Metric | EVO | TBLA |
|---|---|---|
| Price | $2.86 | $4.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.00 | $5.00 |
| AVG Volume (30 Days) | 91.4K | ★ 2.8M |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.37 | $7.63 |
| Revenue Next Year | $10.05 | $5.25 |
| P/E Ratio | ★ N/A | $42.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $2.84 |
| 52 Week High | $4.80 | $5.26 |
| Indicator | EVO | TBLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 68.77 |
| Support Level | $2.63 | $3.86 |
| Resistance Level | $3.78 | $5.26 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 33.38 | 77.45 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.